ArticleEuropean urology2021

Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study.

Arshvin Kesavan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.